Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The TRIUMPH-1 results, released May 21, 2026, are topline data that have not yet been peer-reviewed or published in a medical journal
Ginsenoside Rh4 is an active metabolite of triterpenoid saponins in Panax ginseng C.A.Mey
This injectable form was first approved by the FDA in December 2017 for the treatment of type 2 diabetes, reducing the risk of major cardiovascular events in patients with type 2 diabetes and cardiovascular disease, and reducing the risk of kidney disease progression and cardiovascular death in patients with type 2 diabetes and chronic kidney disease
acknowledges the support of the Banting and Best Diabetes Centre Novo Nordisk Chair in Incretin Biology, the Sinai Health-Novo Nordisk Foundation Fund in regulatory peptides and CIHR grant number 154321
These medications are necessary for many diabetics to help maintain their blood sugar levels in a safe range
US$ 26.98
US$ 27.51
US$ 29.90
US$ 22.20
US$ 26.57
US$ 24.86
US$ 21.91
